Genmab | GEN - Net Income


Genmab reported DKK303M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Agios Pharmaceuticals USD -100.7M 1.59M Jun/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 3.86B 1.49B Sep/2026
argenx SE USD 506M 34M Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Bayer EUR -672M 891M Sep/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Demant DKK 1.18B 758M Jun/2026
Exelixis USD 218.1M 6.04M Sep/2026
Fresenius Medical Care EUR 160M 58.38M Sep/2026
Genmab DKK 303M 250M Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
GN Store Nord DKK -22M 933M Jun/2026
GRIFOLS EUR 162M 8M Sep/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Lakefront Biotherapeutics EUR 2.11M 12.38M Jun/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 490M 169M Jun/2026
Novartis USD 1.2B 2.06B Sep/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
UCB EUR 1.08B 608M Dec/2025